Novo Nordisk ... trial, and in phase 1b testing showed an encouraging safety profile, as well as early signs of functional cardiac benefits, including a reduction in the heart failure biomarker ...

EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of ...

Shelby Knowles / Bloomberg / Getty Images Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy ... course of a 72-week trial. That translates ...

Novo Nordisk ... trial versus Eli Lilly's tirzepatide. Additional trials could also be initiated in metabolic dysfunction-associated steatohepatitis ('MASH'), alcoholic liver disease, heart ...

In an oral presentation on 7 December, 52-week results from the phase 2 part of the ongoing phase 2/3 HIBISCUS trial of etavopivat ... at 08.30 PST. From Novo Nordisk’s haemophilia portfolio ...

Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new ... Wegovy over the course of a 72-week trial. That translates to an average roughly ...

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their ... compounds were pitted in a head-to-head clinical trial. Wednesday, the answer finally arrived as Lilly ...

After slashing the U.S. prices of several of its insulin products by 75% at the start of 2024, Novo Nordisk is ending the year by announcing similar price reductions for most of its other insulins ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47 per cent more weight than those who were given Novo Nordisk ... apnoea or heart disease. None of the trial subjects ...

This message is part of a critical review of cell-based and cell product-based therapies for the treatment of heart failure. The review details 20 years of completed and ongoing clinical trials.

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish ...